Breast Cancer Connect
  • Saved

2yr

Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis

Source : https://doi.org/10.1016/j.clbc.2023.09.002

The results of the currently ongoing trials with CDK4/6 inhibitors will help obtain additional data to evaluate any differences among the different CDK4/6 inhibitors and clarify the weight of TE adverse events in the benefit/risk balance of this new adjuvant strategy.

  • 2yr
    nothing really new but it was generally associated with Tamoxifen not other agents
  • Saved

2yr
CDK4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer: a Rapid Health Technology Assessment

CDK4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer: a Rapid Health Technology Assessment

Source : https://journals.lww.com/md-journal/fulltext/2023/10060/cdk4_6_inhibitors_for_hormone.89.aspx

n the clinic. Methods: Depending on the Rapid Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions (the Second Edition), a percentage quantitative scoring approach was used to objectively...

Until the clinical studies, guideline recommendations, prices, and many other aspects of this assessment are updated, abemaciclib and palbociclib, which have the top 2 scores, can be used as a priority recommendation for Chinese medical institutions to select CDK4/6 inhibitors and optimize the use of the drug catalog based on the scoring...

  • Saved

2yr
Abemaciclib Plus Trastuzumab With or Without Fulvestrant Versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women With HR+, HER2+ Advanced Breast Cancer: Plain Language Summary of the MonarcHER Study

Abemaciclib Plus Trastuzumab With or Without Fulvestrant Versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women With HR+, HER2+ Advanced Breast Cancer: Plain Language Summary of the MonarcHER Study

Source : https://www.futuremedicine.com/doi/10.2217/fon-2023-0078

No summary available.

The data from the monarcHER study suggest that the combination of abemaciclib, trastuzumab, and fulvestrant may offer a chemotherapy-free option for patients with HR+, HER2+ ABC who have experienced worsening of disease despite multiple prior therapies.

  • 2yr
    Treatment of ER+/Her2+ tumors is an area of the major unmet need, This approach is likely to be useful and there is article to help to secure insurance coverage
  • Saved

2yr
Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients With HR+/HER2- Metastatic Breast Cancer

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients With HR+/HER2- Metastatic Breast Cancer

Source : https://pubmed.ncbi.nlm.nih.gov/37760527/

CDK4/6-inhibitors have demonstrated similar efficacy and are considered an effective first-line endocrine treatment of patients with hormone-receptor positive (HR+)/human-epidermal-growth-factor-receptor-2 negative (HER2-) metastatic breast cancer (MBC) in the endpoint of progress...

Findings from this indirect treatment comparison suggest no significant PFS or OS differences between CDK4/6-inhibitors in postmenopausal patients with HR+/HER2- MBC.

  • 2yr
    very nice; I always suspected so, but Verzenio is more toxic
  • Saved

2yr

Cost-Effectiveness Analysis of Abemaciclib With Endocrine Therapy (ET) Versus ET Alone for HR+, HER2−, Node-Positive, High-Risk Early Breast Cancer in Italy

Source : https://journals.aboutscience.eu/index.php/grhta/article/view/2561

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

Abemaciclib plus ET is a cost-effective treatment option vs ET alone for those with HR+, HER2− node-positive EBC at high risk of recurrence in Italy.

  • 2yr
    if EU feels it is cost effective it may be. I am not sure how different is the price of Verzenio in EU vs US. it very well could be Show More